Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Consolidated Net Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Consolidated Net Income for 12 consecutive years, with -$62.0 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income fell 4.7% to -$62.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.5 million through Dec 2025, up 15.02% year-over-year, with the annual reading at -$351.5 million for FY2025, 15.03% up from the prior year.
  • Consolidated Net Income for Q4 2025 was -$62.0 million at ImmunityBio, up from -$67.3 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$59.2 million in Q4 2024, with the low at -$233.4 million in Q4 2023.
  • Average Consolidated Net Income over 5 years is -$105.8 million, with a median of -$95.2 million recorded in 2022.
  • The sharpest move saw Consolidated Net Income crashed 115.47% in 2023, then skyrocketed 74.65% in 2024.
  • Over 5 years, Consolidated Net Income stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then plummeted by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then decreased by 4.7% to -$62.0 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$62.0 million, -$67.3 million, and -$92.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.